Changchun High-tech: Subsidiary gains approval for listing of Brolong tablets domestically.

Changchun High-tech Announcement: Subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" issued by the National Medical Products Administration, and its application for Tibolone tablets has been approved for marketing in China. Tibolone tablets are a tissue-selective estrogenic activity regulator developed by Jinsai Pharmaceutical, belonging to the category of chemical drugs in the form of oral tablets, used for treating low estrogen symptoms caused by natural or surgical menopause in women.